-$0.68 Earnings Per Share Expected for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) This Quarter

Wall Street analysts expect that Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTGet Rating) will announce earnings per share (EPS) of ($0.68) for the current quarter, according to Zacks. Zero analysts have issued estimates for Rocket Pharmaceuticals’ earnings. The highest EPS estimate is ($0.64) and the lowest is ($0.76). Rocket Pharmaceuticals posted earnings of ($0.55) per share during the same quarter last year, which would suggest a negative year over year growth rate of 23.6%. The company is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Rocket Pharmaceuticals will report full-year earnings of ($2.70) per share for the current year, with EPS estimates ranging from ($2.80) to ($2.60). For the next financial year, analysts expect that the company will post earnings of ($2.36) per share, with EPS estimates ranging from ($3.19) to ($1.47). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Rocket Pharmaceuticals.

Rocket Pharmaceuticals (NASDAQ:RCKTGet Rating) last posted its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.04. During the same quarter in the prior year, the business earned ($0.65) earnings per share.

A number of equities analysts have weighed in on RCKT shares. William Blair reiterated an “outperform” rating on shares of Rocket Pharmaceuticals in a research report on Thursday, May 5th. SVB Leerink upped their price target on shares of Rocket Pharmaceuticals from $64.00 to $66.00 and gave the stock an “outperform” rating in a research report on Friday, May 20th. Zacks Investment Research lowered shares of Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 27th. Stifel Nicolaus upped their target price on shares of Rocket Pharmaceuticals from $63.00 to $67.00 in a research report on Thursday, May 19th. Finally, Chardan Capital upped their target price on shares of Rocket Pharmaceuticals from $60.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday, May 19th. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $64.25.

In related news, insider Jonathan David Schwartz sold 45,000 shares of the company’s stock in a transaction on Wednesday, March 30th. The shares were sold at an average price of $16.41, for a total transaction of $738,450.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 36.50% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in RCKT. Wells Fargo & Company MN raised its stake in Rocket Pharmaceuticals by 2.2% during the second quarter. Wells Fargo & Company MN now owns 26,388 shares of the biotechnology company’s stock valued at $1,169,000 after purchasing an additional 560 shares in the last quarter. BlackRock Inc. raised its stake in shares of Rocket Pharmaceuticals by 1.5% in the third quarter. BlackRock Inc. now owns 3,218,491 shares of the biotechnology company’s stock valued at $96,199,000 after acquiring an additional 48,359 shares during the period. Alliancebernstein L.P. raised its stake in shares of Rocket Pharmaceuticals by 170.3% in the third quarter. Alliancebernstein L.P. now owns 148,272 shares of the biotechnology company’s stock valued at $4,432,000 after acquiring an additional 93,425 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Rocket Pharmaceuticals by 30.4% in the third quarter. Goldman Sachs Group Inc. now owns 967,597 shares of the biotechnology company’s stock valued at $28,922,000 after acquiring an additional 225,292 shares during the period. Finally, US Bancorp DE raised its stake in shares of Rocket Pharmaceuticals by 32.3% in the third quarter. US Bancorp DE now owns 7,790 shares of the biotechnology company’s stock valued at $233,000 after acquiring an additional 1,902 shares during the period.

Shares of RCKT traded up $1.36 during mid-day trading on Friday, reaching $11.60. The stock had a trading volume of 44,724 shares, compared to its average volume of 584,525. The firm has a market cap of $763.72 million, a price-to-earnings ratio of -4.27 and a beta of 1.92. Rocket Pharmaceuticals has a 12 month low of $7.57 and a 12 month high of $49.66. The business has a fifty day moving average of $12.56 and a 200 day moving average of $17.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.68 and a current ratio of 15.68.

Rocket Pharmaceuticals Company Profile (Get Rating)

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

Featured Stories

Get a free copy of the Zacks research report on Rocket Pharmaceuticals (RCKT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Rocket Pharmaceuticals (NASDAQ:RCKT)

Want More Great Investing Ideas?

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.